AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TAK
  4. [6-K] Takeda Pharmaceutical Company Limited American Current Report (Foreign Issuer)

[6-K] Takeda Pharmaceutical Company Limited American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K


FORM 6-K


U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of July 2025

 Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐


Information furnished on this form:
EXHIBIT
Exhibit
Number
99.1
Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: July 31, 2025By:/s/ Norimasa Takeda
Norimasa Takeda
Chief Accounting Officer and Corporate Controller


Source:

Stock TAK logo
Takeda Pharm

NYSE:TAK

TAK Rankings

#303 Ranked by Market Cap
#773 Ranked by Dividends

TAK Latest News

Jul 30, 2025
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Jul 21, 2025
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
Jul 14, 2025
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Jun 30, 2025
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
Jun 25, 2025
Takeda Announces New Assignments of Directors

TAK Latest SEC Filings

Jul 30, 2025
[6-K] Takeda Pharmaceutical Company Limited American Current Report (Foreign Issuer)
Jul 14, 2025
[6-K] Takeda Pharmaceutical Company Limited American Current Report (Foreign Issuer)
Jul 9, 2025
[144] Takeda Pharmaceutical Company Limited American SEC Filing
Jul 9, 2025
[144] Takeda Pharmaceutical Company Limited American SEC Filing
Jul 9, 2025
[144] Takeda Pharmaceutical Company Limited American SEC Filing

TAK Stock Data

47.59B
3.16B
0.01%
2.5%
0.26%
Drug Manufacturers - Specialty & Generic
Healthcare
Japan
Tokyo